

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Leishmania metacaspase: an arginine-specific peptidase.

Authors: Martin R, Gonzalez I, Fasel N

Journal: Methods in molecular biology (Clifton, N.J.)

Year: 2014

Volume: 1133

Pages: 189-202

DOI: 10.1007/978-1-4939-0357-3_12

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Metadata of the chapter that will be visualized online

Chapter Title	Leishmania Metacaspase: An Arginine-Specific Peptidase	
Copyright Year	2014	
Copyright Holder	Springer Science+Business Media New York	
Author	Family Name	Martin
	Particle	
	Given Name	Ricardo
	Suffix	
	Division	Department of Biochemistry
	Organization	University of Lausanne
	Address	Ch. des Boveresses 155, 1066, Epalinges, Switzerland
Author	Family Name	Gonzalez
	Particle	
	Given Name	Iveth
	Suffix	
	Division	Department of Biochemistry
	Organization	University of Lausanne
	Address	Ch. des Boveresses 155, 1066, Epalinges, Switzerland
Corresponding Author	Family Name	Fasel
	Particle	
	Given Name	Nicolas
	Suffix	
	Division	Department of Biochemistry
	Organization	University of Lausanne
	Address	Ch. des Boveresses 155, 1066, Epalinges, Switzerland
Abstract	<p>The purpose of this chapter is to give insights into metacaspase of <i>Leishmania</i> protozoan parasites as arginine-specific cysteine peptidase. The physiological role of metacaspase in <i>Leishmania</i> is still a matter of debate, whereas its peptidase enzymatic activity has been well characterized. Among the different possible expression systems, metacaspase-deficient yeast cells (<i>Δyca1</i>) have been instrumental in studying the activity of <i>Leishmania major</i> metacaspase (LmjMCA). Here, we describe techniques for purification of LmjMCA and its activity measurement, providing a platform for further identification of LmjMCA substrates.</p>	
Keywords (separated by “-”)	<i>Leishmania</i> - Cysteine peptidase - Arginine-specific peptidase - Metacaspase - Enzymatic assay - Protease inhibitors	

Leishmania Metacaspase: An Arginine-Specific Peptidase

Ricardo Martin, Iveth Gonzalez, and Nicolas Fasel

3

Abstract

4

The purpose of this chapter is to give insights into metacaspase of *Leishmania* protozoan parasites as arginine-specific cysteine peptidase. The physiological role of metacaspase in *Leishmania* is still a matter of debate, whereas its peptidase enzymatic activity has been well characterized. Among the different possible expression systems, metacaspase-deficient yeast cells (*Ayca1*) have been instrumental in studying the activity of *Leishmania major* metacaspase (LmjMCA). Here, we describe techniques for purification of LmjMCA and its activity measurement, providing a platform for further identification of LmjMCA substrates.

5

6

7

8

9

10

11

Key words *Leishmania*, Cysteine peptidase, Arginine-specific peptidase, Metacaspase, Enzymatic assay, Protease inhibitors

12

13

1 Introduction

14

In 2000, Uren et al. described a group of cysteine proteases orthologous to caspases but absent in mammals, which was named metacaspases [1]. Metacaspases belong to the C14 family of CD clan of cysteine proteases [2] and possess caspase-like domain with a highly conserved catalytic dyad of histidine and cysteine. They are divided into two structurally different types: type I metacaspases with an additional N-terminal extension that is similar to initiator/inflammatory caspases and type-II metacaspases with an insertion of around 200 amino acids between two caspase-like subunits. Interestingly, genomic analysis reveals the presence of a large pool of metacaspases in unicellular and filamentous cyanobacteria that are still poorly studied [3], whereas metacaspases from plants, *Saccharomyces cerevisiae*, and protozoan parasites have rather been extensively investigated.

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

Depending on the species, *Leishmania* protozoan parasites induce different forms of diseases ranging from cutaneous, mucocutaneous or visceral leishmaniasis. All the *Leishmania* species express a unique type of metacaspase harboring a central catalytic

30

31

32

domain (containing the conserved catalytic dyad histidine and cysteine) flanked by an N-terminal domain containing a mitochondrial localization signal and a less conserved proline-rich C-terminal domain (61.4–100 % homology), which probably plays a role in protein–protein interactions. Interestingly, although the N-terminal mitochondrial localization signal is functional, most of *Leishmania major* metacaspase (LmjMCA) is detected in the cytoplasm either in a full length or in a processed form corresponding to the central catalytic domain lacking the N- and the C-terminal domains [4].

Due to the mitochondrial localization signal and the proline-rich sequences, LmjMCA N- and C-terminal domains could preclude expression and activity measurement of metacaspase. Therefore, it is necessary to limit expression and activity measurement of LmjMCA to the 251 amino acids (amino-acid residues 63–314 of LmjF35.1580) predictive of the catalytic domain (cd-LmjMCA). To do so, the DNA sequence encoding the catalytic domain was amplified and the PCR product was inserted into the pESC-His vector (Stratagene) using appropriate cloning sites [5]. This vector contains a galactose inducible promoter and N-terminally 6× His and C-terminal FLAG epitope encoding sequences respectively allowing purification with Ni-NTA resin or with murine monoclonal antibodies against the Penta-His-epitope (α -His5; Qiagen) or the FLAG epitope (α -FLAG; Stratagene). A single step was sufficient to enrich for enough material for specific enzymatic activity tests (Subheading 3.6; Fig. 1).

In contrast to caspases that have strict substrate specificity towards aspartic acid, metacaspases rather cleave arginines or lysines at the substrate P1 position [5–8].




Fig. 1 cd-LmjMCA was purified from yeast expressing cells on an Ni-NTA resin and analyzed by 12 % SDS-PAGE and staining with Coomassie or by immunoblotting using the α -5His antibody. Lanes 1–3, Coomassie staining. Lane 1, molecular mass markers; Lane 2, whole cell lysate; Lane 3, cd-LmjMCA purified on Ni-NTA column. Lanes 4 and 5, immunoblotting with anti-5His antibody. Lane 4, whole cell lysate expressing cd-LmjMCA; Lane 5, cd-LmjMCA purified on Ni-NTA column [AU1]




Fig. 2 Enzymatic activity of cd-LmjMCA with the peptidyl substrate Ac-VRPR-AMC. Protein extracts from $\Delta yca1$ yeast cells transformed with the pESC-His vector alone (vector control) and expressing the catalytic domain of LmjMCA (cd-LmjMCA) wild type (wt) and its respective H147A and C202A mutants, were evaluated for their activity towards Ac-VRPR-AMC substrate. The AMC release was measured every 15 min for 2 h to determine the activity as the slope of the resulting linear regression. Relative activity is expressed as the fold-increase relative to the activity of the vector control. Data show mean \pm standard deviation

LmjMCA has been found to be an arginine-specific cysteine protease able to complement the yeast metacaspase (YCA1). In the evaluation of specific recognition of the *A. thaliana* metacaspase AtMC9 using a peptide library, amino acids valine, arginine, proline, and arginine were found to be important in positions P4, P3, P2, and P1, respectively, allowing the design of the optimized tetrapeptide substrate VRPR[9]. To examine the specificity of LmjMCA for this peptide, the catalytic domain of LmjMCA (cd-LmjMCA) can be expressed in $\Delta yca1$ yeast cells and tested with the fluorogenic substrate (Subheading 3.9; Fig. 2).

Enzymatic activity of cd-LmjMCA can be tested in whole yeast cell lysate providing that specific substrates and inhibitors are available. Total protein extracts of $\Delta yca1$ yeast cells expressing cd-LmjMCA were tested for their enzymatic activity with Boc-GRR-AMC, z-GGR-AMC, and Ac-VRPR-AMC substrates in the presence of different inhibitors such as a broad caspase inhibitor z-VAD-fmk, the cysteine protease inhibitor E64, and the serine protease inhibitors PMSF, leupeptin, and aprotinin (Subheading 3.5; Fig. 3). The caspase inhibitor z-VAD-fmk produced a low but significant inhibition of cd-LmjMCA activity with both Boc-GRR-AMC (p value = 0.0008) and z-GGR-AMC (p value < 0.0001) but not with the Ac-VRPR-AMC substrate. The cysteine protease inhibitor E64 had no significant effect on cd-LmjMCA activity with the three substrates. The serine protease inhibitors PMSF and aprotinin had no effect on cd-LmjMCA activity with both Boc-GRR-AMC




Fig. 3 Effect of protease inhibitors on cd-LmjMCA enzymatic activity. Protein extracts from $\Delta yca1$ yeast cells transformed with the pESC-His vector expressing the catalytic domain of LmjMCA (cd-LmjMCA) were tested for enzymatic activity with the Boc-GRR-AMC, Z-GGR-AMC, and Ac-VRPR-AMC substrates in absence or presence of 100 μ M z-VAD-fmk, 100 μ M E64, 10 mM PMSF, 1 mM leupeptin, and 100 μ M aprotinin. The AMC release was measured every 15 min for 2 h to determine the activity as the slope of the resulting linear regression. Relative activity was calculated as the fold increase relative to the activity of the vector control (with and without protease inhibitors). Data show mean \pm standard deviation. * $P < 0.05$

86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103

and z-GGR-AMC substrates, however, cd-LmjMCA activity with the Ac-VRPR-AMC substrate was increased when these two latter inhibitors were added. However, this increase was not always observed. The increase of activity of cd-LmjMCA with the Ac-VRPR-AMC substrate in the presence of PMSF and aprotinin could be due to a protective effect over cd-LmjMCA by inhibition of its degradation by other proteases. Since these experiments were done with total protein extracts, the influence of other yeast proteases cannot be excluded. Interestingly, leupeptin, a serine protease inhibitor, which can also inhibit some cysteine proteases such as calpains and cathepsins, completely abrogated cd-LmjMCA activity with all three substrates (Boc-GRR-AMC p -value < 0.0002 ; z-GGR-AMC p -value < 0.001 ; and Ac-VRPR-AMC p -value < 0.0001). Although the structural similarity of cd-LmjMCA with caspases could explain the slight inhibition found with z-VAD-fmk for Boc-GRR-AMC and z-GGR-AMC, this inhibitor was not able to affect the activity of cd-LmjMCA towards Ac-VRPR-AMC, the most preferred substrate of this metacaspase (Fig. 3).

104 2 Materials

105
106
107

All chemicals used are of Molecular Biology grade unless specified and solutions are prepared with deionized water. When not specified, incubations are performed at room temperature.

2.1 <i>Leishmania</i> Metacaspase Gene	1. <i>L. major</i> metacaspase gene: LmjF.35.1580 (Gene ID: 3684453).	108
2.2 <i>YCA1</i> Disrupted Yeast Cells Expressing cd-LmjMCA	1. Metacaspase disrupted yeast cells: Euroscarf <i>YCA1</i> disrupted strain (<i>yca1</i> Δ cells) Accession Number Y02453 (BY4741; MAT a; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0; YOR197w::kanMX4) transformed with the pESC-His vector (Stratagene, La Jolla) or with the pESC-His expressing LmjMCA or its inactive forms cd-LmjMCA H147A and cd-LmjMCA C202A [5].	109 110 111 112 113 114
	2. Inactive forms of cd-LmjMCA obtained by using the QuikChange® multi site-directed mutagenesis kit (Stratagene).	115 116
2.3 Yeast Media and Transformation	1. YPD medium: 20 g/l Difco peptone, 10 g/l Yeast extract, H ₂ O to 950 ml, pH 6.5. Autoclave, let cool down to 55 °C, and add 50 ml of 40 % glucose filtered through a 0.22 μm size filter (Final concentration of glucose: 2 %).	117 118 119 120
	2. YPD plates: same as YPD medium but supplemented with 20 g/l agar.	121 122
	3. 10× Dropout [4] amino acid solution (without histidine when using the pESC-His vector): 200 mg/ml l-adenine hemisulfate salt, 200 mg/ml l-arginine HCl, 200 mg/ml l-histidine, 300 mg/ml l-isoleucine, 1,000 mg/ml l-leucine, 300 mg/ml l-lysine HCl, 200 mg/ml l-methionine, 500 mg/ml l-phenylalanine, 2,000 mg/ml l-threonine, 200 mg/ml l-tryptophan, 300 mg/ml l-tyrosine, 200 mg/ml l-uracil, 1,500 mg/ml l-valine. Pass the solution through a 0.22 μm size filter and aliquot in 50-ml tubes. Store at 4 °C.	123 124 125 126 127 128 129 130 131
	4. SD/DO/Glucose medium: for 1 L weigh 6.7 g of Yeast nitrogen base without amino acids and add H ₂ O to 850 ml. Control the pH (pH 5.8). Autoclave and let cool down to 55 °C. Add 100 ml of the 10× DO solution (without histidine) and then 50 ml of 40 % glucose or galactose (filtered; final concentration 2 %).	132 133 134 135 136 137
	5. SD/DO/Glucose plates: same as SD/DO medium (without histidine) supplemented with 20 g/l agar.	138 139
	6. 10× TE: 0.1 M Tris-HCl, 10 mM EDTA, pH 7.5. Pass the solution through a 0.22 μm filter and store at -20 °C.	140 141
	7. 10× LiAc: 1 M LiAc, pH 7.5. Pass the solution through a 0.22 μm filter and store at -20 °C.	142 143
	8. 1× TE/1× LiAc solution: 500 μl 10× TE, 500 μl 10× LiAc, adjust to 4 ml with H ₂ O. Use freshly prepared solution.	144 145
	9. PEG 1,000/Tris/LiAc solution: 4 ml of 50 % PEG 1,000 solution, 500 μl 10× TE, and 500 μl 10× LiAc.	146 147
	10. 87 % glycerol.	148

149 **2.4 Yeast Lysis (TCA**
150 **Protocol) and Protein**
151 **Extraction (Glass**
152 **Beads) for SDS-PAGE**
153 **Analysis**

1. Solution B: 3.67 ml H₂O, 925 µl 10 M NaOH, 370 µl β-Mercaptoethanol, 50 µl 100 mM PMSF in isopropanol, 50 µl 0.5 M EDTA/KOH, pH 7.0.
2. Trichloroacetic acid (TCA).
3. Acetone.
4. Lysis buffer: 0.5 % NP40, 20 mM HEPES, pH 8.0, 84 mM KCl, 10 mM MgCl₂, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 5 µg/ml Aprotinin, 5 µg/ml Leupeptin, 1 µg/ml Pepstatin, 1 mM PMSF.
5. Pierce BCA protein assay kit (Thermo Scientific) with BSA as standard.

160 **2.5 Enzymatic**
161 **Activity Test in Whole**
162 **or Purified Cell Lysates**

1. Lysis buffer for whole cell lysate activity test: 50 mM KH₂PO₄, pH 7.5, 500 mM NaCl, 1 mM EDTA, 5 mM DTT, 1 % CHAPS, 5 µg/ml Aprotinin.
2. Lysis buffer for purified cell lysate activity test: 50 mM NaH₂PO₄, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 % Triton X-100.
3. Washing Buffer for purified cell lysate activity test: 50 mM NaH₂PO₄, pH 8.0, 300 mM NaCl, 20 mM imidazole.
4. Elution Buffer for purified cell lysate activity test: 50 mM NaH₂PO₄, pH 8.0, 300 mM NaCl, 250 mM imidazole).
5. Amicon Ultra-4 centrifugal device (Millipore).
6. Base buffer: 150 mM NaCl, 25 mM HEPES, 10 % glycerol, pH 7.5. Store at 4 °C.
7. 10 % CHAPS solution: 1 g CHAPS in 10 ml H₂O. Store at 4 °C.
8. Activity buffer for whole cell lysate activity test: 3.92 ml Base buffer, 40 µl 10 % CHAPS, 20 µl 2 M DTT.
9. Activity buffer for purified cell lysate activity test: 3.52 ml Base buffer, 40 µl 10 % CHAPS, 20 µl 2 M DTT, 400 µl 1 M CaCl₂.
10. Fluorogenic substrates: Boc-Gly-Arg-Arg-7-amino-4-methylcoumarin (Boc-GRR-AMC), Z-Gly-Gly-Arg-7-amino-4-methylcoumarin (Z-GGR-AMC) (both from Bachem AG, Switzerland), and *N*-acetyl-Val-Arg-Pro-Arg-7-amino-4-methylcoumarin (Ac-VRPR-AMC) (Sigma).
11. Protease inhibitors: Benzyloxycarbonyl-Val-Ala-Asp (1010) fluoromethylketone (z-VAD-fmk), E64, PMSF, leupeptin, and aprotinin.
12. Trypsin powder (Boehringer Mannheim GmbH, Germany).
13. 96-well black plates (Optiplate-96 F, PerkinElmer).
14. Spectrophotometer.

2.6 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE)

1. The Bio-Rad Power Pac 3000 system or similar. 190
2. Separating gel (12 %): mix 1.625 ml H₂O, 2 ml 30 % acrylamide–Bis-acrylamide solution (29.2:0.8 acrylamide–Bis-acrylamide), 1.3 ml 1.5 M Tris/HCl buffer, pH 8.8, 25 µl 20 % SDS; 50 µl 10 % ammonium persulfate (APS) and 2 µl tetramethylethylenediamine (TEMED). 191–195
3. Stacking gel (3.9 %): mix 2.64 ml H₂O, 0.67 ml 30 % acrylamide–Bis-acrylamide solution, 0.5 ml 1 M Tris/HCl buffer, pH 6.8, 20 µl 20 % SDS; 40 µl 10 % APS, 8 µl TEMED, and 20 µl bromophenol blue. 196–199
4. 4× Tris/HCl/SDS solution: 91 g Tris base, 2 g SDS, 500 ml H₂O, pH 8.8. 200–201
5. 2× SDS sample loading buffer (100 ml final volume): 25 ml 4× Tris/HCl/SDS solution, 20 ml glycerol, 4 g SDS, 2 ml β-Mercaptoethanol (or 3.1 g DTT), 1 mg bromophenol blue, adjust to 100 ml with H₂O. 202–205
6. 10× SDS electrophoresis running buffer: 250 mM Tris base, 1.92 M glycine, 1 % SDS. Adjust pH to pH 8.3 when diluting to 1×. 206–208
7. Gel staining solution: 50 % methanol, 0.05 % Coomassie Brilliant Blue R-250, 10 % acetic acid. 209–210
8. Gel destaining solution: 5 % methanol, 7 % acetic acid. 211

2.7 Western Blotting

1. The Bio-Rad Power Pac 3000 system or similar. 212
2. 10× gel transfer buffer: 250 mM Tris base, 1.92 M glycine. 213
3. 1× gel transfer buffer solution: 10 ml 10× gel transfer buffer, 20 ml methanol, pH 8.3–8.4, adjust to 1 L with H₂O. 214–215
4. Nitrocellulose membrane (Whatman, GE Healthcare Life sciences or similar). 216–217
5. Filter paper, cut to the size of the gel. 218
6. Ponceau S Solution: 0.5 g Ponceau S, 1 ml glacial acetic acid, adjust to 100 ml with H₂O. 219–220
7. 1× Tris Buffered Saline supplemented with tween 20 (TBST): 25 mM Tris, 150 mM NaCl, 3 mM KCl, pH 7.5, 0.1 % Tween 20. 221–223
8. Blocking buffer: 1× TBST, 5 % nonfat dry milk (NFDM). 224
9. Primary antibody: 1/200 anti-Flag antibody or 1/1,000 anti-Histidine antibody in TBST with 1 % NFDM. 225–226
10. Secondary antibody: 1/2,500 horseradish peroxidase-conjugated antibody in TBST with 1 % NFDM. 227–228
11. Glass plate. 229
12. ECL Western Blotting Detection Reagent (GE Healthcare). 230

- 231 13. Filter papers.
232 14. Plastic wrap.
233 15. Cassette and X-Ray film.

234 3 Methods

235 3.1 Yeast 236 Transformation

- 237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
1. Plate *Dyca1* cells (*see Note 1*) from frozen stock onto YPD plates using a platinum loop, which has been previously sterilized by flaming and then cooled quickly on the plate.
 2. Incubate at 30 °C for 4 days and then inoculate 1 ml of YPD medium with 1 colony and vortex for 2 min.
 3. Transfer to 49 ml of YPD medium (total volume 50 ml) and place on a shaker at 30 °C overnight.
 4. The next day, dilute the overnight culture to OD₆₀₀ 0.2–0.3 in 300 ml (*see Note 2*) and further incubate at 30 °C with shaking for 2 h or until OD₆₀₀ reaches 0.4–0.6.
 5. Centrifuge at 1,000 × *g* for 5 min in 50 ml tubes, dilute and pool pellets in 50 ml H₂O, centrifuge at 1,000 × *g* for 5 min at room temperature.
 6. Resuspend pellet in 1.5 ml of 1× TE/1× LiAc fresh solution.
 7. Add 10 µl of 10 mg/ml herring sperm carrier DNA in a 1.5-ml vial, heat at 95 °C for 5 min and quick chill on ice.
 8. Leave on ice and add 1 µg of cd-LmjMCA plasmid and mix.
 9. Add 100 µl of yeast cell suspension and vortex.
 10. Add 600 µl of PEG1000/Tris/LiAc fresh solution and vortex for 10 s.
 11. Incubate at 30 °C with shaking for 30 min.
 12. Add 70 µl of DMSO from stock solution and mix by inversion at 42 °C for 15 min (heat shock).
 13. Leave on ice for 2 min, then microfuge at 10,000 × *g* for 5 s.
 14. Resuspend the pellet in 500 µl of 1× TE.
 15. Dilute with 1× TE and plate 100 µl of dilutions 1:1, 1:10, 1:100, and 1:1,000 on YPD plates and incubate at 30 °C for 3 days to obtain colonies.
 16. Verify that the transformation was efficient and that your cells have the desired plasmid by using standard minilysate protocol.
 17. Grow overnight culture: inoculate one transformed colony into 1 ml of SD/DO/Glucose medium, vortex, transfer to 9 ml of SD/DO/Glucose medium, and incubate at 30 °C with continuous shaking overnight.
 18. Prepare frozen stock of transformed yeast cells: mix 700 µl of the overnight culture and 300 µl of 87 % glycerol, mix and store at –70 °C.

3.2 Induction of the cd-LmjMCA Expression in Transformed Yeast Cells

1. Inoculate one transformed colony into 1 ml of SD/DO/Glucose medium and vortex. 272
273
2. Transfer to 9 ml of SD/DO/Glucose medium and incubate at 30 °C with continuous shaking overnight. 274
275
3. Dilute overnight culture to OD₆₀₀ 0.05–0.1 in 10 ml (*see Note 3*) in a 100-ml Erlenmeyer flask (ten times culture volume) and incubate at 30 °C with shaking for 6 h or until OD₆₀₀ reaches 0.4–0.6. 276
277
278
279
4. Centrifuge 1 ml of culture at 10,000×g for 1 min and store pellet at –70 °C (non induced control). 280
281
5. For the galactose induction, centrifuge the culture at 1,000×g for 5 min and dilute the pellet with 10 ml of SD/DO/Galactose medium and then incubate at 30 °C with shaking overnight. 282
283
284
285
6. Measure OD₆₀₀ after at least 16 h of induction. 286
7. Centrifuge the culture at 1,000×g for 5 min and store pellet at –70 °C (galactose induced culture) until use. 287
288
8. The pellets are ready for lysis and analysis. 289

3.3 Yeast Lysis (TCA Protocol) for SDS-PAGE Analysis

1. Dilute frozen pellet of the 10 ml cultures (non-induced and galactose induced) with 500 µl of 1× TE and centrifuge at 10,000×g for 1 min at 4 °C. 290
291
292
2. Resuspend the pellet with 500 µl of H₂O and add 75 µl of Solution B. 293
294
3. Shake 10 min at 4 °C and add 280 µl of 72 % TCA. 295
4. Put on ice for 5 min and then centrifuge at 10,000×g for 10 min at 4 °C. 296
297
5. Add 700 µl of acetone to the pellet and centrifuge at 10,000×g for 10 min at 4 °C. 298
299
6. Repeat the wash with acetone. 300
7. Let dry the pellet and then resuspend in 50 µl of 1× PBS (*see Note 4*). 301
302
8. Store at –70 °C until use. 303

3.4 Yeast Protein Extraction (Glass Beads)

1. Dilute frozen pellet with 50 µl of lysis buffer, transfer to a 1.5-ml vial with 0.08 g glass beads. 304
305
2. Vortex ten times, 1 min each, and collect supernatant. 306
3. Wash beads with 50 µl of lysis buffer and collect supernatant. 307
4. Pool supernatants and centrifuge at 10,000×g for 1 h at 4 °C. 308
5. Collect and store supernatant at –70 °C in lysis buffer containing protease inhibitors. 309
310
6. Protein concentration in supernatant can be measured using a BCA protein assay reagent with BSA as standard. 311
312

313 **3.5 cd-LmjMCA**
314 **Enzymatic Activity in**
315 **Whole Yeast Cell**
316 **Lysate**

1. Harvest transformed yeast cells from a 50 ml culture following 24 h of induction. The pellet can be kept frozen at -70°C .
2. Resuspend the frozen pellet in 100 μl of lysis buffer, transfer to a 1.5-ml vial and add 0.08 g of glass beads.
3. Vortex ten times, 1 min each.
4. Collect and save supernatant.
5. Wash the beads with 50 μl of lysis buffer, collect and save supernatant.
6. Pool supernatants and centrifuge at $10,000\times g$ for 1 h at 4°C . Collect and store supernatant at -70°C in lysis buffer containing protease inhibitors.
7. Measure protein concentration in the supernatant using a BCA protein assay reagent with BSA as standard.
8. For one black-plate well, add 196 μl of Activity buffer and 4 μl of 10 $\mu\text{g}/\mu\text{l}$ total protein extract (40 μg total protein per well). Prepare duplicate or triplicate wells.
9. Dilute 50 mM of substrate-AMC to 5 mM with Activity buffer and add 2 μl of diluted substrate per well (final concentration 50 μM). Read fluorescence each 15 min for 2 h at 24°C with 360 nm excitation and 460 nm emission wavelengths.
10. As a positive control use 10 ng of trypsin per well in the 200 μl reaction volume. As negative controls, use protein extracts from yeast cells transformed with the pESC-His vector or expressing cd-LmjMCA (H147A) and cd-LmjMCA (C202A).
11. Determine enzymatic activity by calculating the slope of the linear regression. Express results in arbitrary milli-fluorescence units per minute per μg of protein (mFU/min/ μg), or as the fold increase relative to the activity of the vector control (*see Note 5*).
12. To test the effect of different protease inhibitors on the enzymatic activity, supplement activity reactions with the following concentrations of inhibitors: 100 μM z-VAD-fmk, 100 μM E64, 10 mM PMSF, 1 mM leupeptin, and 100 μM aprotinin.

346 **3.6 Purification of**
347 **Leishmania**
348 **Metacaspase Catalytic**
349 **Domain (cd-LmjMCA)**
350 **from Yeast on Ni-NTA**
351 **Resin**

1. Resuspend frozen pellet from a 500 ml culture after induction with galactose for 18 h in 2.5 ml of lysis buffer.
2. Add 2.5 g of glass beads (0.25–0.5 mm) and vortex ten times, 1 min each (*see Note 6*).
3. Collect and save supernatant.
4. Wash the glass beads with 2.5 ml of lysis buffer, collect and save supernatant.
5. Pool the supernatants, centrifuge at $10,000\times g$ for 1 h at 4°C , and save supernatant (contains soluble proteins).

353
354

6. Wash 1 ml 50 % Ni-NTA resin with 2 ml of lysis buffer and add the supernatant (soluble proteins) to the washed resin. 355
356
7. Incubate overnight at 4 °C on a wheel. 357
8. Centrifuge at 1,000×g for 5 min at 4 °C, wash the resin twice with 500 µl of Washing Buffer. 358
359
9. Elute protein by adding three aliquots of 500 µl of Elution Buffer and then pool the eluates. 360
361
10. Centrifuge the three pooled elutions at 10,000×g for 1 min at 4 °C. 362
363
11. Pool the supernatants and concentrate eluted proteins in 1× PBS with an Amicon Ultra-4 centrifugal device prior to protein concentration measurement. 364
365
366
12. Store at −80 °C until use for the activity test. 367

3.7 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE)

1. Wash gel glass plates and mount the electrophoresis system according to manufacturer’s protocol. 368
369
2. Prepare separating gel, fill to the three quarters the glass plate, add some isopropanol on the gel to obtain a flat surface and wait for the gel to polymerize. 370
371
372
3. Prepare stacking gel, fill the gel glass plate up to the edge, insert the comb and wait for the gel to polymerize. 373
374
4. Mix each sample (20 µg of total protein from yeast lysates) with 2× SDS sample loading buffer in a ratio 1:1 (v/v), boil samples for 5 min at 95 °C, spin in microfuge and load on the gel. 375
376
377
5. Run gel for 20 min at 80 V and then for 45 min at 180 V with chamber on ice. 378
379
6. Stain the gel with Coomassie Blue (*see Note 7*): Soak the gel in a staining solution and incubate with shaking at room temperature for 1 h to overnight. 380
381
382
7. Soak the gel in a destaining solution and incubate with shaking at room temperature for 30 min. Repeat until background disappears. Store the gel in water or dry (*see Notes 8 and 9*). 383
384
385

3.8 Western Blotting

1. Equilibrate the gel, four filter papers, and sponges in 1× transfer buffer. 386
387
2. Mount a sandwich in the following way: white sponge, two filter papers, nitrocellulose membrane, gel, two filter papers, green sponge (white sponge oriented to the cathode—red face). 388
389
390
3. Remove bubbles by rolling a 15-ml tube over the sandwich. 391
4. Run in 1× transfer buffer for 1 h at 100 V with chamber on ice. 392
5. After protein transfer, incubate the nitrocellulose membrane on a shaker at room temperature for 5 min in Ponceau S Solution. 393
394
395

- 396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
6. Incubate on the shaker at room temperature for 2 min in water to remove excess of Ponceau S red.
 7. Take a picture and mark molecular weights with a pencil.
 8. Incubate on a shaker at room temperature for 10 min in water to complete destaining.
 9. Incubate the membrane on the shaker for 1 h at room temperature or overnight at 4 °C in the blocking buffer.
 10. Incubate the membrane on a shaker overnight at 4 °C with the first antibody.
 11. Wash four times for 15 min each with TBST.
 12. Incubate the membrane on a shaker for 1 h at room temperature with the secondary antibody.
 13. Wash four times for 15 min each with TBST (*see Note 10*).
 14. For membrane development, deposit the membrane on a clean glass plate.
 15. Dry quickly with a filter paper.
 16. Overlay 1.5 ml of a developing solution (1:1 of ECL solutions A:B for a 0.125 ml/cm² membrane) and wait for 2 min.
 17. Dry with a filter paper and cover the membrane with a plastic wrap.
 18. Insert the membrane in a cassette and expose to an X-Ray film for different times (e.g. 2 s, 10 s, 2 min, 10 min); develop the film (*see Note 11*).

419 **3.9 cd-LmjMCA**
420 **Activity Measurement**
421 **with the Ac-VRPR-**
422 **AMC Substrate**

- 423
424
425
426
427
428
429
430
431
432
433
434
1. Use 1 µg of purified protein in a total 200 µl volume per well of a 96-well black plate.
 2. Add 196 µl of activity buffer and 1–4 µl of Ni-NTA purified cd-LmjMCA per well. Prepare duplicate or triplicate wells.
 3. Dilute Ac-VRPR-AMC in Activity buffer to the final concentration 5 mM and add 2 µl of diluted substrate per well (final concentration 50 µM). Read fluorescence each 15 min for 2 h at 24 °C with 360 nm excitation and 460 nm emission wavelengths.
 4. As a positive control use 10 ng of trypsin per well in the 200 µl reaction volume.
 5. Determine enzymatic activity by calculating the slope of the linear regression. Express results in arbitrary milli-fluorescence units per minute per µg of protein (mFU/min/µg), or as the fold increase relative to the activity of the vector control (*see Note 5*).

4 Notes

435

1. *Lycal* cells can be obtained from Euroscarf Accession Number Y02453. 436
437
2. ~10 ml overnight culture in 290 ml of YPD medium. 438
3. ~400 μ l overnight culture in 9.6 ml of SD/DO/Glucose medium 439
440
4. Protein concentration can be measured using the BCA protein assay reagent (Pierce Biotechnology, Inc., Rockford, IL) with BSA as standard. 441
442
443
5. Enzymatic activity tests must be performed at least three times and means and standard deviations must be calculated. The Student *t* test is used in statistical analysis and significance is considered when $p < 0.05$. 444
445
446
447
6. Use 1 g of beads per 1 ml of lysis buffer. 448
7. Detection limit is 0.3–1 μ g/protein band. 449
8. First dilute Coomassie Blue in methanol. 450
9. If you want to keep your gel (after staining), we suggest to put a plastic sheet (candy wrap plastic) over a filter paper; Put the gel over the plastic sheet and soak with water; Put another plastic sheet over the gel; Perforate with a needle around the gel border; Put it on the desiccator at 70 °C under vacuum for 1 h. 451
452
453
454
455
456
10. For competitive blot, first incubate with the peptide at 10 μ g/ml, then add antibody and incubate on wheel 60 for min at room temperature. 457
458
459
11. Stripping membranes: 15 min shaking in 0.1 M of glycine–HCl pH 2–3; rinse with 1 M of NaCl in 1 \times PBS; wash 2 \times 5 min in 1 \times TBS–0.1 % Tween-20; rinse with H₂O; expose film for 10 min to detect former signal. If there is no signal the membrane is ready to be blocked and exposed to a new primary antibody. 460
461
462
463
464
465

Acknowledgements

466

The authors are grateful to the members of the Fasel's group and to Dr. Frank Madeo who provided the pFM21 construct, which served as a control. This work was funded by the grants FNRS N^o 3100A0-116665/1 and IZ70Z0-131421 to NF. 467
468
469
470

471 **References**

- 472 1. Uren AG, O'Rourke K, Aravind LA, Pisabarro 499
 473 MT, Seshagiri S, Koonin EV, Dixit VM (2000) 500
 474 Identification of paracaspases and metacaspases: 501
 475 two ancient families of caspase-like proteins, 502
 476 one of which plays a key role in MALT lymphoma. *Mol Cell* 6(4):961–967 503
 477
 478 2. Mottram JC, Helms MJ, Coombs GH, Sajid M 504
 479 (2003) Clan CD cysteine peptidases of parasitic 505
 480 protozoa. *Trends Parasitol* 19(4):182–187 506
 481
 482 3. Jiang Q, Qin S, Wu QY (2010) Genome-wide 507
 483 comparative analysis of metacaspases in unicel- 508
 484 lular and filamentous cyanobacteria. *BMC* 509
 485 *Genomics* 11:198. doi:10.1186/1471-2164- 510
 486 11-198 511
 487
 488 4. Zalila H, Gonzalez IJ, El-Fadili AK, Delgado 512
 489 MB, Desponds C, Schaff C, Fasel N (2011) 513
 490 Processing of metacaspase into a cytoplasmic 514
 491 catalytic domain mediating cell death in 515
 492 *Leishmania major*. *Mol Microbiol* 79(1):222– 516
 493 239. doi:10.1111/j.1365-2958.2010.07443.x 517
 494
 495 5. Gonzalez IJ, Desponds C, Schaff C, Mottram 518
 496 JC, Fasel N (2007) *Leishmania major* meta- 519
 497 caspase can replace yeast metacaspase in pro- 520
 498 grammed cell death and has arginine-specific 521
 522 cysteine peptidase activity. *Int J Parasitol* 523
 524 37(2):161–172. doi:10.1016/j.ijpara.2006. 524
 525 10.004 525
6. Vercammen D, van de Cotte B, De Jaeger G, 499
 Eeckhout D, Casteels P, Vandepoele K, 500
 Vandenberghe I, Van Beeumen J, Inze D, Van 501
 Breusegem F (2004) Type II metacaspases 502
 Atmc4 and Atmc9 of *Arabidopsis thaliana* 503
 cleave substrates after arginine and lysine. *J Biol* 504
Chem 279(44):45329–45336. doi:10.1074/ 505
jbc.M406329200 506
 7. Watanabe N, Lam E (2005) Two *Arabidopsis* 507
 metacaspases AtMCP1b and AtMCP2b are 508
 arginine/lysine-specific cysteine proteases and 509
 activate apoptosis-like cell death in yeast. *J Biol* 510
Chem 280(15):14691–14699. doi:10.1074/ 511
jbc.M413527200 512
 8. Lee N, Gannavaram S, Selvapandiyar A, 513
 Debrabant A (2007) Characterization of meta- 514
 caspases with trypsin-like activity and their puta- 515
 tive role in programmed cell death in the 516
 protozoan parasite *Leishmania*. *Eukaryot Cell* 517
 6(10):1745–1757. doi:10.1128/EC.00123-07 518
 9. Vercammen D, Belenghi B, van de Cotte B, 519
 Beunens T, Gavigan JA, De Rycke R, 520
 Brackenier A, Inze D, Harris JL, Van 521
 Breusegem F (2006) Serpin1 of *Arabidopsis* 522
thaliana is a suicide inhibitor for metacaspase 523
 9. *J Mol Biol* 364(4):625–636. doi:10.1016/j. 524
jmb.2006.09.010 525